CurveBeam AI Ltd (ASX: CVB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
CurveBeam AI Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$34.94 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
373.39 million
Earnings per share
-0.884
Dividend per share
N/A
Year To Date Return
-55.13%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
CurveBeam AI Ltd (ASX: CVB)
Latest News
Small Cap Shares
Bell Potter is tipping huge returns from these small cap ASX shares
CVB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About CurveBeam AI Ltd
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
CVB Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Nov 2024 | $0.11 | $0.00 | 0.00% | 88,222 | $0.11 | $0.11 | $0.11 |
| 19 Nov 2024 | $0.11 | $0.01 | 9.52% | 717,496 | $0.10 | $0.11 | $0.10 |
| 18 Nov 2024 | $0.11 | $-0.02 | -16.67% | 140,585 | $0.12 | $0.12 | $0.11 |
| 15 Nov 2024 | $0.12 | $0.01 | 9.09% | 1,051,239 | $0.11 | $0.12 | $0.10 |
| 14 Nov 2024 | $0.11 | $-0.01 | -8.33% | 81,475 | $0.13 | $0.13 | $0.11 |
| 13 Nov 2024 | $0.12 | $0.01 | 9.09% | 151,073 | $0.11 | $0.12 | $0.11 |
| 12 Nov 2024 | $0.11 | $0.01 | 10.00% | 415,781 | $0.11 | $0.11 | $0.11 |
| 11 Nov 2024 | $0.10 | $0.00 | 0.00% | 61,617 | $0.10 | $0.10 | $0.10 |
| 08 Nov 2024 | $0.10 | $0.00 | 0.00% | 91,529 | $0.10 | $0.11 | $0.10 |
| 07 Nov 2024 | $0.10 | $-0.01 | -9.09% | 540,017 | $0.12 | $0.12 | $0.10 |
| 06 Nov 2024 | $0.11 | $-0.01 | -8.33% | 299,499 | $0.13 | $0.13 | $0.11 |
| 05 Nov 2024 | $0.12 | $0.01 | 9.09% | 233,056 | $0.11 | $0.12 | $0.11 |
| 04 Nov 2024 | $0.11 | $0.02 | 21.74% | 1,537,794 | $0.10 | $0.12 | $0.10 |
| 01 Nov 2024 | $0.09 | $0.00 | 0.00% | 749,732 | $0.09 | $0.10 | $0.09 |
| 31 Oct 2024 | $0.09 | $-0.02 | -18.18% | 995,326 | $0.11 | $0.11 | $0.09 |
| 30 Oct 2024 | $0.11 | $-0.01 | -8.33% | 312,220 | $0.12 | $0.12 | $0.11 |
| 29 Oct 2024 | $0.12 | $-0.01 | -7.69% | 438,413 | $0.14 | $0.14 | $0.12 |
| 28 Oct 2024 | $0.13 | $0.00 | 0.00% | 214,416 | $0.13 | $0.13 | $0.13 |
| 25 Oct 2024 | $0.13 | $-0.01 | -7.41% | 162,025 | $0.14 | $0.14 | $0.13 |
| 24 Oct 2024 | $0.14 | $-0.01 | -7.14% | 71,138 | $0.15 | $0.15 | $0.14 |
| 23 Oct 2024 | $0.14 | $-0.02 | -12.90% | 110,406 | $0.16 | $0.16 | $0.14 |
| 22 Oct 2024 | $0.16 | $0.01 | 6.67% | 85,693 | $0.15 | $0.16 | $0.15 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 31 Oct 2024 | Hashan Silva | Issued | 11,111,111 | $1,999,999 |
Placement.
|
| 16 Oct 2024 | Arun Singh | Buy | 332,280 | $48,206 |
As advised by the company. Contingent Merger Consideration,usd$
|
| 16 Oct 2024 | Arun Singh | Buy | 744,132 | $107,957 |
As advised by the company. Contingent Merger Consideration, US$
|
| 13 Feb 2024 | Kate Robb | Issued | 109,375 | $52,500 |
Director remuneration.
|
| 13 Feb 2024 | Robert Lilley | Issued | 72,917 | $35,000 |
Director remuneration. 104,167 share rights
|
| 13 Feb 2024 | Arun Singh | Issued | 268,840 | $107,804 |
Issue of securities. vwap, 268,840 Share Rights
|
| 13 Feb 2024 | Hashan Silva | Issued | 109,375 | $52,500 |
Director remuneration.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Kate Robb | Non-Executive Director | Apr 2023 |
Ms Robb has over 25 years of finance, governance, risk management and compliance experience. Ms Robb previously served as a non-executive director and chair of the audit committee of unlisted public company Sandringham Community Financial Services Ltd, a Bendigo Bank Community Bank. She is Chair of the Risk Committee.
|
| Mr Robert Lilley | Non-Executive ChairmanNon-Executive Director | Apr 2021 |
Mr Lilley has over 35 years of experience in the medical device and diagnostics industries. Mr Lilley previously served as senior vice president of global sales and marketing for Digene Corporation, a molecular diagnostics company, which was subsequently acquired by Qiagen N.V. He is a member of the Risk Committee.
|
| Mr Arun Singh | Chief Operating OfficerChief Technology OfficerExecutive DirectorPresident | Mar 2023 |
Mr Singh has over 34 years of experience in the advanced imaging technology industry, with a focus on medical imaging. Since 2009, he has served as President and Chief Executive Officer of CurveBeam US, prior to which Mr Singh co-founded and served as the Vice President and Chief Technology Officer of Imaging Sciences International Inc. (ISI), which was subsequently acquired by Danaher Corporation.
|
| Mr Hashan De Silva | Non-Executive Director | Oct 2021 |
Mr Silva is an experienced sell side and buy side investor in the Australian healthcare sector. Previously he held roles such as the head of healthcare research at Karst Peak, an investment management firm based in Sydney and Hong Kong, which has a focus on biotechnology, health technology, medical devices and diagnostics. He is a member of the Risk Committee.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 67,419,801 | 18.50% |
| Citicorp Nominees Pty Limited | 46,739,868 | 12.83% |
| KP TMF ASA 2 \C | 21,857,867 | 6.00% |
| Arun Singh | 20,561,672 | 5.64% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 12,577,575 | 3.45% |
| Gregory Wayne Brown | 11,048,024 | 3.03% |
| Susmita Singh Arun Singh Family A/C> | 10,444,231 | 2.87% |
| Arun Singh Arun Singh Family A/C> | 9,034,709 | 2.48% |
| UBS Nominees Pty Ltd | 6,661,601 | 1.83% |
| J P Morgan Nominees Australia Pty Limited | 6,023,194 | 1.65% |
| Capital M Group Ii Llc | 4,891,426 | 1.34% |
| Apex Fund Services Pty Ltd Frazis Venture Fund A/C> | 4,621,452 | 1.27% |
| Gregory Wayne Brown G W Brown Sf A/C> | 4,542,500 | 1.25% |
| Seego Pty Ltd | 4,094,528 | 1.12% |
| Ilwella Pty Ltd | 3,405,102 | 0.93% |
| Uwe Mundry and Sigrid Mundry Uwe Sigrid Mundry Rev A/C> | 3,370,593 | 0.93% |
| UM Commercialisation Pty Ltd | 3,260,000 | 0.89% |
| BNP Paribas Noms Pty Ltd | 3,070,707 | 0.84% |
| Robert Mcg Lilley Robert Mcg Lilley A/C> | 2,902,217 | 0.80% |
| Francois Lintz | 2,865,040 | 0.79% |
